Hyosung TNS IPO Official Corporate Statement
12.11.2020 18:00:00 EET | Business Wire | Press release
Hyosung TNS, the Hyosung America parent company, has announced its intention to launch an initial public offering (“IPO”) on the Korean stock exchange. The exact timing, size and structure of the offering has not been finalized but the Hyosung Corporation, the South Korean holding company, intends to remain the majority owner of Hyosung TNS. KB Securities Co. and Daishin Securities Co. have been selected as the lead managers for this effort.
The IPO will play a key role in Hyosung Corporation’s growth strategy by capturing the full market potential of the Hyosung TNS business which has delivered strong financial results over the last three years. The IPO will increase global brand recognition, further expand R&D investments for technology innovation and fuel global expansion with the target to become the global market leader.
Over the last 30 years, Hyosung Corporation has grown into a global business through diversification and a core commitment to its customers’ satisfaction and success. Hyosung TNS is and will continue to be an important and integral part of Hyosung Corporation’s growth strategy.
Hyosung TNS has a diversified portfolio of solutions for the Retail and Financial Institution markets and is the ATM market leader in the United States, Russia, South Korea, Indonesia and Nigeria while transacting business in 30 countries globally. The company has planned expansion into Europe, South America, Middle East and Africa.
The company’s innovative solution portfolio includes ATMs, teller cash recyclers, core integrated self-service, multi-vendor software applications, retail kiosks, self-checkout systems, professional services and maintenance services. Software is a growing business for the company. Recently, the largest financial institution in India placed its trust in Hyosung TNS to provide multi-vendor ATM software to operate a fleet of over 40,000 ATMs from a variety of hardware providers.
Hyosung TNS’s position as an industry leader is attributable to the company’s technology expertise, innovation leadership, best-in-class partner network and an unwavering commitment to customer success. Hyosung TNS uniquely owns all aspects of design and manufacturing for its products allowing the company to bring new technology to the market faster. The company’s Research and Development focus is on innovating in the areas of financial services technology such as next generation recycling and new branch transformation solutions, enterprise cloud-based software solutions such as cash management and predictive managed services toolsets, and self-checkout technology.
“Today’s announcement further clarifies the intent and expectations of the upcoming IPO,” said Scott Hackl, Executive Vice President. “This is an exciting time for all of us at Hyosung.”
For more information about the company go to hyosung-tns.com or hyosungamericas.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005076/en/
Contact information
Sara Burgos:
sara@shiromasouthwest.com
Sharon Shaw:
sharon.shaw@nhausa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 13:07:00 EEST | Press release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 02:17:00 EEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
Grindr Nominates Three New Directors to Its Board of Directors1.5.2026 00:16:00 EEST | Press release
Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced the nomination of Rob Solomon, Lisa Gersh, and Fadi Hanna to stand for election to its Board of Directors at the Annual Meeting of Shareholders on June 2, 2026. Rob Solomon is a deeply seasoned technology CEO and operator in consumer internet and marketplaces. He has held CEO and COO roles at scaled platforms including GoFundMe, Groupon, and Kayak-predecessor SideStep, and is currently CEO of leading electric aviation company H55. Lisa Gersh is a CEO and long-tenured public company director with deep experience across consumer brands, media, and commerce. She has served on the Hasbro (NASDAQ: HAS) board since 2010 and has led businesses including Oxygen Media, GOOP, and Alexander Wang. Fadi Hanna is Chief Risk Officer at Bloomberg L.P., overseeing enterprise risk across the organization. He previously worked at J.P. Morgan and has served on the board of Immigration Equality. “Over the last few years, we bu
The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’30.4.2026 23:42:00 EEST | Press release
The Empire State Building (ESB), the “World’s Most Famous Building,” will celebrate its 95th anniversary on May 1, 2026, with new offers at the Empire State Building Observation Deck, a special birthday tower lighting display, and a slate of celebrations to honor its legacy and future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430693323/en/ The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’ “The Empire State Building celebrates its 95th anniversary, still the ‘World’s Most Famous Building,’ a modernized, sustainability leader as technologically advanced today as the day she was completed, and the winner of #1 Top Attraction in the United States in Tripadvisor’s Travelers’ Choice Awards for 2026,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. Anniversary Offerings and Experiences To mark its 95th anniversary, the Empire State Building will debut new experiences
MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis30.4.2026 23:17:00 EEST | Press release
MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH002, the Company’s lead rationally designed Live Biotherapeutic Product (LBP) candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate ulcerative colitis (UC). MH002 today is the most advanced LBP targeting inflammatory bowel disease (IBD)-specific mechanisms and is composed of a rationally designed microbial consortium of six well-characterized commensal strains. The FDA’s Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important drugs to patients earlier. Fast Track designation enables frequent communication with the FDA to discuss the drug's development plan and ensure collection o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom